Heart Failure TNM-Like Classification by Fedele, Francesco et al.
Journal of the American College of Cardiology Vol. 63, No. 19, 2014
 2014 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2014.02.552VIEWPOINT
Heart Failure
TNM-Like Classiﬁcation
Francesco Fedele, MD, Paolo Severino, MD, Simone Calcagno, MD, Massimo Mancone, MD, PHD
Rome, ItalySFrom the Departm
and Geriatric Scie
Rome, Italy.
Manuscript recetaging of heart failure represents a major issue in clinical practice. In this setting, the MOGE(S) classiﬁcation was
designed to be similar to the TNM classiﬁcation used in oncology. Nevertheless, MOGE(S) nosology differs greatly
from the key elements of the TNM classiﬁcation, as well as its simplicity and clinical applicability. In fact, MOGE(S)
acronym stands for morphofunctional characteristics (M), organ involvement (O), genetic or familial inheritance
pattern (G), etiological information (E), and functional status (S). Recently, a new TNM-like classiﬁcation for heart
failure was proposed. This classiﬁcation, named HLM, refers to heart damage arising from an initial stage of
impaired systolic or diastolic function, without structural injury, to an advanced stage of biventricular dysfunction (H),
different stages of lung involvement (L), and malfunction of peripheral organs such as the kidney, liver, and brain
(M). HLM classiﬁcation was inﬂuenced by the key elements of TNM staging: simplicity, clinical usefulness, efﬁcacy
for planning a therapeutic strategy, and ability to determine patient prognosis. HLM classiﬁcation seems to be easily
applied in the real world and valuable for balancing economic resources with the clinical complexity of
patients. (J Am Coll Cardiol 2014;63:1959–60) ª 2014 by the American College of Cardiology FoundationRecently, an interesting nosology, the MOGE(S) classiﬁca-
tion, was published (1) that addresses the different charac-
teristics of cardiomyopathies. It associates morphofunctional
characteristics (M), organ involvement (O), genetic or fa-
milial inheritance pattern (G), and etiological (E) informa-
tion on a genetic defect or underlying disease/cause (i.e.,
viral, autoimmune, toxicity); it also provides data on the
functional status (S) using the American College of Cardi-
ology/American Heart Association (ACC/AHA) stage and
New York Heart Association (NYHA) functional classes.
We read with interest the article by Arbustini et al. (1)
that describes cardiomyopathies as “disorders characterized
by morphologically and functionally abnormal myocardium
in the absence of any other disease that is sufﬁcient,
by itself, to cause the observed phenotype.” However, as the
authors assumed, the MOGE(S) classiﬁcation could be
complex in the beginning, mostly in clinical practice. In
fact, the MOGE(S) example MD[AVB] OH GADEG-LMNA
[p. Arg190Trp] should be interpreted as the classiﬁcation for
a patient presenting with an early hypertrophic cardiomy-
opathy with heart involvement, autosomal dominant trans-
mission, genetic etiology, caused by the p.Arg403Glu
mutation of the MYH7 gene, with the ACC/AHA stage A
and NYHA functional class I. We agree with the com-
mentary of Elliott (2), which stated that “the concept ofent of Cardiovascular, Respiratory, Nephrology, Anesthesiology
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grading of tumors, staging is used to plan treatment and to
indicate prognosis,” referred to the Arbustini et al. (1)
classiﬁcation. In fact, we believe that MOGE(S) nosology
differs greatly from the key elements of TNM classiﬁcation,
as well as its simplicity and clinical applicability. We believe
that the values of the TNM classiﬁcation are simplicity,
clinical usefulness, efﬁcacy for planning a therapeutic strat-
egy, and skill in determining a patient’s prognosis. Having
these goals in mind, we proposed a staging system for heart
failure (HF) similar to the TNM classiﬁcation used in
oncology (3). It aimed to grade heart failure in order to plan
treatment and evaluate prognosis in a very simple way as well
as with the TNM. In our proposed HLM classiﬁcation, the
ﬁrst step, where “H” for heart, may be analogous with “T” in
the TNM classiﬁcation. The second step in this HF staging
is the assessment of lung involvement “L”. For the func-
tional and anatomic proximity of the lungs to the heart, they
may be indeed considered, continuing the analogy, as a
lymph node station. Finally, remembering the etymological
meaning of “metastasis,” which in Ancient Greek meant
“what is beyond there,” similar to the concept used in
oncology for metastasis, the “malfunction” of peripheral
organs such as the kidney, liver, and brain may represent the
ﬁnal step “M” (Fig. 1).
In conclusion, the MOGE(S) nosology represents a
translation link between basic science and clinical medicine.
However, this classiﬁcation differs greatly from the goals of
TNM, as we trust that it seems to be too complex to be used
in the clinical practice. On the other hand, our classiﬁcation
Figure 1 HLM Classiﬁcation
In each column, different stages of heart (H-1 to H-4), lung (L-0 to L-3), and peripheral organ involvement (i.e., kidney, liver, and brain [M-0 to M-3]) are shown. *The Cardiac Lung
is the arterialization of precapillary and postcapillary pulmonary vasculature and it is easy to imagine how this condition maximally compromises the respiratory function.
EF ¼ ejection fraction; HF ¼ heart failure; LV ¼ left ventricle; mPAP ¼ mean pulmonary arterial pressure; PAWP ¼ pulmonary artery wedge pressure. Adapted with permission
from Fedele et al. (3).
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1960seems to be easily applicable in the real world and would
deserve the adjective “TNM-like.” Nevertheless, further
clinical and scientiﬁc validation is needed.
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